|
1.
|
|
19 p, 1.5 MB |
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
/
Wieduwilt, M.J. (University of Oklahoma) ;
Metheny, L. (University Hospitals Seidman Cancer Center) ;
Zhang, M.J. (Medical College of Wisconsin) ;
Wang, H.L. (Center for International Blood and Marrow Transplant Research) ;
Estrada-Merly, N. (Center for International Blood and Marrow Transplant Research) ;
Marks, D.I. (University Hospitals Bristol National Health Service Trust) ;
Samer Al-Homsi, A. (New York University Langone Health) ;
Muffly, L. (Stanford University) ;
Chao, N. (Duke University Medical Center) ;
Rizzieri, D. (Duke University) ;
Gale, R.P. (Imperial College London) ;
Gadalla, S.M. (National Institutes of Health) ;
Cairo, M. (New York Medical College) ;
Mussetti, Alberto (Institut d'Investigacio Biomedica de Bellvitge) ;
Gore, S. (Yale New Haven Hospital) ;
Bhatt, V.R. (University of Nebraska Medical Center) ;
Patel, S.S. (University of Utah) ;
Michelis, F.V. (Princess Margaret Cancer Centre) ;
Inamoto, Y. (National Cancer Center Hospital) ;
Badawy, S.M. (Northwestern University Feinberg School of Medicine) ;
Copelan, E. (Atrium Health) ;
Palmisiano, N. (Thomas Jefferson University) ;
Kharfan-Dabaja, M.A. (Mayo Clinic) ;
Lazarus, H.M. (Case Western Reserve University) ;
Ganguly, S. (University of Kansas Health System) ;
Bredeson, C. (The Ottawa Hospital Transplant and Cellular Therapy Program) ;
Perez, M.A.D. (Hospital Infantil Universitario Niño Jesus) ;
Cassaday, R. (University of Washington) ;
Savani, B.N. (Vanderbilt University Medical Center) ;
Ballen, K. (Division of Hematology/Oncology. University of Virginia Health System) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Wirk, B. (Penn State Cancer Institute) ;
Bacher, U. (University of Bern) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital Center and Research) ;
Bashey, A. (Northside Hospital) ;
Murthy, H.S. (Mayo Clinic) ;
Yared, J.A. (University of Maryland) ;
Aldoss, I. (City of Hope Medical Center) ;
Farhadfar, N. (University of Florida College of Medicine) ;
Liu, H. (University of Chicago Medicine) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Waller, E.K. (Emory University) ;
Solh, M. (Northside Hospital) ;
Seftel, M.D. (University of British Columbia) ;
van der Poel, M. (Maastricht University Medical Center) ;
Grunwald, M.R. (Atrium Health) ;
Liesveld, J.L. (University of Rochester Medical Center) ;
Kamble, R.T. (Baylor College of Medicine) ;
McGuirk, J. (University of Kansas Health System) ;
Munker, R. (University of Kentucky) ;
Cahn, Jean-Yves (Universite Grenoble Alpes) ;
Lee, J.W. (The Catholic University of Korea) ;
Freytes, C.O. (University of Texas Health Science Center) ;
Krem, M.M. (University of Kentucky) ;
Winestone, L.E. (University of California) ;
Gergis, U. (Thomas Jefferson University) ;
Nathan, S. (Rush University Medical Center) ;
Olsson, R.F. (Karolinska Institutet) ;
Verdonck, L.F. (Isala Clinic) ;
Sharma, A. (St. Jude Children's Research Hospital) ;
Ringden, O. (Karolinska Institutet) ;
Friend, B.D. (Baylor College of Medicine) ;
Cerny, J. (University of Massachusetts Medical Center) ;
Choe, H. (The Ohio State University Wexner Medical Center) ;
Chhabra, S. (Center for International Blood and Marrow Transplant Research) ;
Nishihori, T. (Moffitt Cancer Center) ;
Seo, S. (Dokkyo Medical University) ;
George, B. (Christian Medical College) ;
Baxter-Lowe, L.A. (Children's Hospital Los Angeles) ;
Hildebrandt, G.C. (University of Kentucky) ;
de Lima, M. (University Hospitals Case Medical Center) ;
Litzow, M. (Mayo Clinic Rochester) ;
Kebriaei, P. (The University of Texas MD Anderson Cancer Center) ;
Hourigan, C.S. (National Institutes of Health) ;
Abid, M.B. (Medical College of Wisconsin) ;
Weisdorf, D.J. (University of Minnesota) ;
Saber, W. (Center for International Blood and Marrow Transplant Research) ;
Universitat Autònoma de Barcelona
The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. [...]
2022 -  10.1182/bloodadvances.2021004916
Blood advances, Vol. 6 Núm. 1 (november 2022) , p. 339-357
|
|
|
2.
|
|
10 p, 680.7 KB |
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma
/
Ahmed, Sairah (University of Texas) ;
Kanakry, Jennifer A. (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) ;
Ahn, Kwang Woo (Medical College of Wisconsin) ;
Litovich, Carlos Alejandro (Medical College of Wisconsin) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Aljurf, Mahmoud Deeb (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Bacher, Vera Ulrike (Inselspital. Bern University Hospital) ;
Bejanyan, Nelli (Immunotherapy. Moffitt Cancer Center) ;
Cohen, Jonathon B. (Emory University School of Medicine) ;
Farooq, Umar (University of Iowa Hospitals and Clinics) ;
Fuchs, Ephraim Joseph (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) ;
Bolaños-Meade, Javier (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) ;
Ghosh, Nilanjan S. (Levine Cancer Institute. Atrium Health) ;
Herrera, Alex F. (City of Hope National Medical Center) ;
Hossain, Nasheed (Loyola University Chicago-Stritch School of Medicine) ;
Inwards, David (Mayo Clinic) ;
Kanate, Abraham Sebastian (West Virginia University) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Munshi, Pashna (Georgetown University Hospital) ;
Murthy, Hemant S. (University Florida College of Medicine) ;
Mussetti, Alberto (Institut Català d'Oncologia-Hospitalet) ;
Nieto, Yago (University of Texas) ;
Perales, Miguel-Angel (Memorial Sloan Kettering Cancer Center) ;
Romee, Rizwan (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Seo, Sachiko (Dokkyo Medical University) ;
Wirk, Baldeep Mona (Seattle Cancer Care Alliance) ;
Yared, Jean A. (University of Maryland) ;
Sureda, Anna (Institut Català d'Oncologia-Hospitalet) ;
Fenske, Timothy S. (Medical College of Wisconsin) ;
Hamadani, Mehdi (Medical College of Wisconsin) ;
Universitat Autònoma de Barcelona
Classic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched sibling donor (MSD). Herein, we compare outcomes of 2 reduced-intensity conditioning (RIC) HCT platforms in cHL: T cell-replete related donor haploidentical (haplo) HCT with a post-transplant cyclophosphamide (PTCy)-based approach versus an MSD/calcineurin inhibitor (CNI)-based approach. [...]
2019 - 10.1016/j.bbmt.2019.05.025
Biology of blood and marrow transplantation, Vol. 25 Núm. 9 (september 2019) , p. 1859-1868
|
|
|
3.
|
|
14 p, 1.0 MB |
Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia
/
Albasanz-Puig, Adaia (Hospital Universitari de Bellvitge) ;
Durà-Miralles, Xavier (Hospital Universitari de Bellvitge) ;
Laporte-Amargós, Júlia (Hospital Universitari de Bellvitge) ;
Mussetti, Alberto (Hospital Universitari de Bellvitge) ;
Ruiz-Camps, Isabel (Hospital Universitari Vall d'Hebron) ;
Puerta-Alcalde, Pedro (Hospital Clínic i Provincial de Barcelona) ;
Abdala, Edson (Instituto do Câncer do Estado de São Paulo) ;
Oltolini, Chiara (IRCCS San Raffaele Scientific Institute (Milà, Itàlia)) ;
Akova, Murat (Hacettepe University School of Medicine) ;
Montejo, José Miguel (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Mikulska, Malgorzata (University of Genoa (DISSAL) and Ospedale Policlinico San Martino) ;
Martín-Dávila, Pilar (Hospital Universitario Ramón y Cajal (Madrid)) ;
Herrera, Fabián (Centro de Educación Médica e Investigaciones Clínicas (CEMIC)) ;
Gasch Blasi, Oriol (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Drgona, Lubos (Comenius University and National Cancer Institute) ;
Morales, Hugo Manuel Paz (Hospital Erasto Gaertner) ;
Brunel, Anne-Sophie (Lausanne University Hospital) ;
García, Estefanía (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Isler, Burcu (Istanbul Education and Research Hospital) ;
Kern, Winfried V. (University of Freiburg Medical Center) ;
Retamar-Gentil, Pilar (Universidad de Sevilla) ;
Aguado, José María (Instituto de Investigación Hospital "12 de Octubre" (i + 12)) ;
Montero, Milagros (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Kanj, Souha S. (American University of Beirut Medical Center) ;
Sipahi, Oguz R. (Ege University) ;
Calik, Sebnem (University of Health Science Izmir Bozyaka Training and Research Hospital) ;
Márquez-Gómez, Ignacio (Hospital Regional Universitario de Málaga) ;
Marin, Jorge I. (Clínica Maraya (Pereira, Colòmbia)) ;
Gomes, Marisa Z. R. (Hospital Federal dos Servidores do Estado) ;
Hemmati, Philipp (Klinikum Ernst von Bergmann) ;
Araos, Rafael (Alemana Universidad del Desarrollo) ;
Peghin, Maddalena (University of Udine and Azienda Sanitaria Universitaria Integrata) ;
Del Pozo, Jose Luis (Clínica Universidad de Navarra) ;
Yáñez, Lucrecia (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Tilley, Robert (University Hospitals Plymouth NHS Trust (Regne Unit)) ;
Manzur, Adriana (Hospital Rawson) ;
Novo, Andres (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Pallarès, Natàlia (Hospital Universitari de Bellvitge) ;
Bergas, Alba (Hospital Universitari de Bellvitge) ;
Carratalà, Jordi (Hospital Universitari de Bellvitge) ;
Gudiol, Carlota (Hospital Universitari de Bellvitge) ;
Universitat Autònoma de Barcelona
To assess the effect of combination antibiotic empirical therapy on 30-day case-fatality rate in neutropenic cancer patients with Pseudomonas aeruginosa (PA) bacteremic pneumonia. This was a multinational, retrospective cohort study of neutropenic onco-hematological patients with PA bloodstream infection (BSI) (2006-2018). [...]
2022 - 10.3390/microorganisms10040733
Microorganisms, Vol. 10 (march 2022)
|
|
|
4.
|
|
12 p, 927.8 KB |
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
/
Kwon, Mi (Hospital General Universitario Gregorio Marañón) ;
Iacoboni, Gloria (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Reguera-Ortega, Juan Luis (Instituto de Biomedicina de Sevilla) ;
Corral, Lucía López (Instituto de Investigación Biomédica de Salamanca) ;
Morales, Rafael Hernani (Hospital Clínic Universitari (València)) ;
Ortiz-Maldonado, Valentín (Hospital Clínic i Provincial de Barcelona) ;
Guerreiro, Manuel (Hospital Universitari i Politècnic La Fe (València)) ;
Caballero, Ana Carolina (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Domínguez, María Luisa Guerra (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Pina, Jose Maria Sanchez (Hospital Universitario 12 de Octubre (Madrid)) ;
Mussetti, Alberto (Institut Català d'Oncologia) ;
Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bastos, Mariana (Hospital General Universitario Gregorio Marañón) ;
Catala, Eva (Vall d'Hebron Institut d'Oncologia) ;
Delgado, Javier (Instituto de Biomedicina de Sevilla) ;
Henriquez, Hugo Luzardo (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Sanz, Jaime (Hospital Universitari i Politècnic La Fe (València)) ;
Calbacho, Maria (Hospital Universitario 12 de Octubre (Madrid)) ;
Bailén, Rebeca (Hospital General Universitario Gregorio Marañón) ;
Carpio Segura, Cecilia del Carmen (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Ribera Santasusana, Jose Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sureda, Anna (Institut Català d'Oncologia) ;
Briones Meijide, Javier (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Hernandez-Boluda, Juan Carlos (Hospital Clínic Universitari (València)) ;
Cebrián, Nuria Martínez (Hospital Clínic i Provincial de Barcelona) ;
Martin, Jose Luis Diez (Universidad Complutense de Madrid) ;
Martín, Alejandro (Instituto de Investigación Biomédica de Salamanca) ;
Barba, Pere (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. [...]
2022 - 10.3324/haematol.2022.280805
Haematologica, Vol. 108 (january 2023) , p. 110-121
|
|
|
5.
|
|
10 p, 674.7 KB |
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma
/
Iacoboni, Gloria (Vall d'Hebron Institut d'Oncologia) ;
Villacampa Javierre, Guillermo (Vall d'Hebron Institut d'Oncologia) ;
Martinez-Cibrian, Nuria (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Bailén, Rebeca (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Lopez Corral, Lucia (Centro de Investigación del Cáncer-IBMCC) ;
Sanchez, Jose M. (Hospital Universitario 12 de Octubre (Madrid)) ;
Guerreiro, Manuel (Hospital Universitari i Politècnic La Fe (València)) ;
Caballero, Ana Carolina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mussetti, Alberto (Institut Català d'Oncologia) ;
Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Hernani, Rafael (Hospital Clínic Universitari (València)) ;
Abrisqueta, Pau (Vall d'Hebron Institut d'Oncologia) ;
Solano, Carlos (University of Valencia) ;
Sureda, Anna (Institut Català d'Oncologia) ;
Briones Meijide, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martín García-Sancho, Alejandro (Centro de Investigación del Cáncer-IBMCC) ;
Kwon, Mi (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Reguera-Ortega, Juan Luis (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Barba, Pere (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Tisagenlecleucel (tisa-cel) is a second-generation autologous CD19-targeted chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. [...]
2021 - 10.1002/cam4.3881
Cancer Medicine, Vol. 10 (may 2021) , p. 3214-3223
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
